Business Model
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development.
 
Nimotuzumab
Anti-cancer antibody that targets the epidermal growth factor receptor, with an improved side-effect profile compared to marketed EGFR-targeting products
AeroLEF®
Proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl
CYT387
Novel JAK1/JAK2 inhibitor for multiple indications including MPNs
CYT997
Novel anti-cancer Vascular Disrupting Agent (VDA)
 
   
consortium
 
science
dosing
 
science
 
clinical trials
 
safety profile
clinical trials
news
events
webcasts

 

September 12-15, 2010

Rodman & Renshaw's 12th Annual Healthcare Conference
New York Palace Hotel
New York, NY
Presenter: Sean Thompson
 

November 19, 2009
4:00 PM (EST)
YM BioSciences Annual General Meeting
of Shareholders
TSX Broadcast Centre Gallery
The Exchange Tower
130 King Street W., Toronto, Ontario
listen to archived webcast | view AGM presentation

presentations
reports
posters & publications

Corporate Presentation
Calendar Second Quarter 2010

Nimotuzumab Proposed Mechanism of Action

The AeroLEF Concept

Fiscal 2010 Third Quarter Results

U.S. Senate Report on Changing Cuba Policy


 

Nimotuzumab, a humanized anti-epidermal growth factor receptor antibody, interacts with EGFRvIII. (2010 AACR Annual Meeting)

111In-labeled nimotuzumab modified with nuclear localization sequences (NLS) for targeting Herceptin® resistant breast cancer cells.
(2010 AACR Annual Meeting)

A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms. (2010 New Directions in Leukaemia Research)